Early recurrence of bladder cancer in the colon after robot-assisted radical cystectomy: Disappearance following dose-dense methotrexate, vinblastine, doxorubicin and cisplatin treatment

Michio Noda, Masaki Nakamura, Taketo Kawai, Yusuke Sato, Yuta Yamada, Yoshiyuki Akiyama, Daisuke Yamada, Motofumi Suzuki, Haruki Kume

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The popularity of robot-assisted radical cystectomy over open radical cystectomy has been increasing because the former, a minimally invasive surgery, contributes to earlier recovery and shorter hospitalization. However, atypical recurrences may be more frequent after robot-assisted radical cystectomy than after open radical cystectomy. We report a case of an atypical early recurrence of bladder cancer including the descending colon. Case presentation: A 70-year-old Japanese man underwent robot-assisted radical cystectomy for muscle-invasive bladder cancer. Four months later, he was hospitalized for severe anemia (hemoglobin, 5.1 g/dL). Colonoscopy revealed a 4-cm submucosal oozing tumor in the descending colon. Computed tomography revealed multiple recurrent lesions including recurrence in the descending colon, all of which disappeared completely after chemotherapy with six cycles of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin. Conclusion: We encountered a rare case of an atypical recurrence of bladder cancer in the colon after robot-assisted radical cystectomy.

Original languageEnglish
Pages (from-to)429-432
Number of pages4
JournalIJU Case Reports
Volume4
Issue number6
DOIs
Publication statusPublished - Nov 2021
Externally publishedYes

Keywords

  • and cisplatin
  • atypical recurrence
  • descending colon
  • dose-dense methotrexate
  • doxorubicin
  • robot-assisted radical cystectomy
  • vinblastine

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Early recurrence of bladder cancer in the colon after robot-assisted radical cystectomy: Disappearance following dose-dense methotrexate, vinblastine, doxorubicin and cisplatin treatment'. Together they form a unique fingerprint.

Cite this